Osteoporosis Market Report and Forecast 2025-2034
Description
The osteoporosis market size in the 7 major markets was valued at USD 13.90 Billion in 2024, driven by increasing innovations and research activities. The market size is anticipated to grow at a CAGR of 3.58% during the forecast period of 2025-2034 to achieve a value of USD 19.76 Billion by 2034.
Osteoporosis Market Overview
Osteoporosis can be characterized by low bone mass, deterioration of bone tissue, bone sterility, and constant risk of fracturing the bones. The most common cause of a broken bone among the elderly is osteoporosis. Bones that are most affected by the condition include the vertebrae in the spine, forearm, the wrist, and the hip. This condition typically exhibits no symptoms until it is diagnosed during the examination of a fractured bone. It makes it hard for the patients to carry out regular daily life activities as a little amount of pressure or stress may result in a broken bone.
The development of new, more effective osteoporosis medications, and advancements in bone density testing, is also driving the osteoporosis market growth. Government support and initiatives aimed at improving bone health and lowering the incidence of osteoporosis-related fractures are also fuelling the market growth.
Prevalence of Osteoporosis to Drive the Market Growth
The market is expected to witness significant growth driven by the increase in the incidence of osteoporosis. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in a fracture every three seconds around the world. The market growth can be further attributed to the growing investment in research and development activities conducted by biotechnology and pharmaceutical companies. The increasing public awareness of the condition is also playing a crucial role in the increasing number of diagnoses, contributing to the osteoporosis market share. Moreover, the market is expected to be driven by the rising technological advancements and drug development, likely to bolster the market growth during the forecast period.
Innovations Expected to Bolster Market Growth
The market is expected to witness significant growth driven by ground-breaking innovations and developments in the forecast period. For instance, in June 2023, the development of a robotic pill that safely delivers injectable osteoporosis drugs. The highly encouraging efficacy has offered hope to individuals suffering from chronic conditions, such as osteoporosis, as the only route of administration currently available is painful injections. This pioneering technology has the potential to revolutionize treatment options for patients, providing a painless alternative to injections.
Technical Advancements to Bolster the Demand
The market growth is expected to be driven by the new technologically advanced developments, exemplified by the development of OsteoBoost by Bone Health Technologies. It is a vibration belt designed to fight osteoporosis and osteopenia. OsteoBoost has been developed on 15 years of published research, including research from NASA. Bone Health Technologies has filed for Class 2 Prescription De Novo Approval with the FDA. Such developments attract investors which plays a crucial role in the market development and stability, likely to aid the osteoporosis market size in the forecast period.
Government Initiatives to Aid the Growth
Additionally, increasing initiatives and efforts by non-government organizations towards creating awareness and providing solutions are collectively contributing to osteoporosis market growth. For instance, in Feb 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an agreement to develop a strategic roadmap on bone health and aging and advocate for a public health strategy to prevent fractures among older people. This partnership with WHO is expected to enhance the prevention and management of osteoporosis at local, regional, and national levels resulting in an enhanced quality of life for individuals living with this condition.
Increasing Research and Clinical Trials Leading New Opportunities
The increasing number of clinical trials to examine the efficacy of a drug is a major factor responsible for the growth of the osteoporosis market value. In May 2023, new research showed how women taking romosozumab, a new anti-osteoporosis drug available on the NHS, might be at risk of a heart attack. The University of Bristol-led study analysed the genetic data on about 34,000 people. Romosomuzab is an effective medicine prescribed to women with severe osteoporosis to reduce the risk of fracture. Discoveries like this are expected to spark discussion among healthcare professionals and researchers to perform more research and find the truth. Additionally, it sparks competition in the market as it brings opportunities for pharmaceutical companies to develop more suitable drugs with no side effects and high efficacy, boosting the market size.
Osteoporosis Market Segmentations
Osteoporosis Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type Germany
France
Italy
Spain
United Kingdom
The United States is dominating the market and is expected to continue dominating the market during the forecast period driven by the presence of key players and the high prevalence of osteoporosis patients in the region. The presence of a robust and high-tech healthcare infrastructure, coupled with the availability of advanced drugs, is expected to drive the osteoporosis market growth.
In November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the approval of a generic version of Forteo in the United States. Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men. Such announcements indicate more affordable options becoming available for treating osteoporosis and accessible to people in need. More affordable options can potentially increase access to osteoporosis treatment, leading to growing demand for these medications.
Osteoporosis Market: Competitor Landscape
In May 2023, Amgen announced that Prolia® (denosumab) injection has been found effective in reducing the risk of fractures in postmenopausal women compared to a common pill treatment called oral alendronate. The announcement was based on new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program. The treatment was also associated with greater reductions in fracture risk over time. Consequentially, doctors and patients are expected to prefer Prolia due to the promising long-term results. This announcement could also encourage further research and development of similar treatments, making more options available to help manage osteoporosis effectively.
The key features of the osteoporosis market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Osteoporosis Market Overview
Osteoporosis can be characterized by low bone mass, deterioration of bone tissue, bone sterility, and constant risk of fracturing the bones. The most common cause of a broken bone among the elderly is osteoporosis. Bones that are most affected by the condition include the vertebrae in the spine, forearm, the wrist, and the hip. This condition typically exhibits no symptoms until it is diagnosed during the examination of a fractured bone. It makes it hard for the patients to carry out regular daily life activities as a little amount of pressure or stress may result in a broken bone.
The development of new, more effective osteoporosis medications, and advancements in bone density testing, is also driving the osteoporosis market growth. Government support and initiatives aimed at improving bone health and lowering the incidence of osteoporosis-related fractures are also fuelling the market growth.
Prevalence of Osteoporosis to Drive the Market Growth
The market is expected to witness significant growth driven by the increase in the incidence of osteoporosis. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in a fracture every three seconds around the world. The market growth can be further attributed to the growing investment in research and development activities conducted by biotechnology and pharmaceutical companies. The increasing public awareness of the condition is also playing a crucial role in the increasing number of diagnoses, contributing to the osteoporosis market share. Moreover, the market is expected to be driven by the rising technological advancements and drug development, likely to bolster the market growth during the forecast period.
Innovations Expected to Bolster Market Growth
The market is expected to witness significant growth driven by ground-breaking innovations and developments in the forecast period. For instance, in June 2023, the development of a robotic pill that safely delivers injectable osteoporosis drugs. The highly encouraging efficacy has offered hope to individuals suffering from chronic conditions, such as osteoporosis, as the only route of administration currently available is painful injections. This pioneering technology has the potential to revolutionize treatment options for patients, providing a painless alternative to injections.
Technical Advancements to Bolster the Demand
The market growth is expected to be driven by the new technologically advanced developments, exemplified by the development of OsteoBoost by Bone Health Technologies. It is a vibration belt designed to fight osteoporosis and osteopenia. OsteoBoost has been developed on 15 years of published research, including research from NASA. Bone Health Technologies has filed for Class 2 Prescription De Novo Approval with the FDA. Such developments attract investors which plays a crucial role in the market development and stability, likely to aid the osteoporosis market size in the forecast period.
Government Initiatives to Aid the Growth
Additionally, increasing initiatives and efforts by non-government organizations towards creating awareness and providing solutions are collectively contributing to osteoporosis market growth. For instance, in Feb 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an agreement to develop a strategic roadmap on bone health and aging and advocate for a public health strategy to prevent fractures among older people. This partnership with WHO is expected to enhance the prevention and management of osteoporosis at local, regional, and national levels resulting in an enhanced quality of life for individuals living with this condition.
Increasing Research and Clinical Trials Leading New Opportunities
The increasing number of clinical trials to examine the efficacy of a drug is a major factor responsible for the growth of the osteoporosis market value. In May 2023, new research showed how women taking romosozumab, a new anti-osteoporosis drug available on the NHS, might be at risk of a heart attack. The University of Bristol-led study analysed the genetic data on about 34,000 people. Romosomuzab is an effective medicine prescribed to women with severe osteoporosis to reduce the risk of fracture. Discoveries like this are expected to spark discussion among healthcare professionals and researchers to perform more research and find the truth. Additionally, it sparks competition in the market as it brings opportunities for pharmaceutical companies to develop more suitable drugs with no side effects and high efficacy, boosting the market size.
Osteoporosis Market Segmentations
Osteoporosis Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Primary Osteoporosis
- Secondary Osteoporosis
- Bisphosphonates
- Selective Estrogen Receptor Modulators
- Parathyroid Hormone Therapy
- RANK Ligand Inhibitors
- Oral
- Injectable
- Others
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
- Hospitals
- Retail Pharmacies
- Online Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Japan
The United States is dominating the market and is expected to continue dominating the market during the forecast period driven by the presence of key players and the high prevalence of osteoporosis patients in the region. The presence of a robust and high-tech healthcare infrastructure, coupled with the availability of advanced drugs, is expected to drive the osteoporosis market growth.
In November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the approval of a generic version of Forteo in the United States. Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men. Such announcements indicate more affordable options becoming available for treating osteoporosis and accessible to people in need. More affordable options can potentially increase access to osteoporosis treatment, leading to growing demand for these medications.
Osteoporosis Market: Competitor Landscape
In May 2023, Amgen announced that Prolia® (denosumab) injection has been found effective in reducing the risk of fractures in postmenopausal women compared to a common pill treatment called oral alendronate. The announcement was based on new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program. The treatment was also associated with greater reductions in fracture risk over time. Consequentially, doctors and patients are expected to prefer Prolia due to the promising long-term results. This announcement could also encourage further research and development of similar treatments, making more options available to help manage osteoporosis effectively.
The key features of the osteoporosis market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- DAIICHI SANKYO COMPANY
- Amgen Inc.
- Merck & Co., Inc
- AbbVie Inc
- Bayer AG
- Johnson & Johnson Services, Inc.
- Sanofi.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Astrazeneca
- Eli Lilly And Company
- Novartis AG
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Osteoporosis Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Osteoporosis Epidemiology Analysis-Seven Major Markets
- 5.1 Epidemiology Overview (2018-2034)
- 5.2 7MM Epidemiology Scenario Overview (2018-2034)
- 5.3 United States Osteoporosis Epidemiology Forecast (2018-2034)
- 5.4 EU-4 and United Kingdom Osteoporosis Epidemiology Forecast (2018-2034)
- 5.4.1 Germany Osteoporosis Epidemiology Forecast (2018-2034)
- 5.4.2 France Osteoporosis Epidemiology Forecast (2018-2034)
- 5.4.3 Italy Osteoporosis Epidemiology Forecast (2018-2034)
- 5.4.4 Spain Osteoporosis Epidemiology Forecast (2018-2034)
- 5.4.5 United Kingdom Osteoporosis Epidemiology Forecast (2018-2034)
- 5.5 Japan Osteoporosis Epidemiology Forecast (2018-2034)
- 6 Osteoporosis Market Overview- Seven Major Markets
- 6.1 Osteoporosis Market Historical Value (2018-2024)
- 6.2 Osteoporosis Market Forecast Value (2025-2034)
- 7 Osteoporosis Market Landscape- Seven Major Markets
- 7.1 Osteoporosis Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Osteoporosis Product Landscape
- 7.2.1 Analysis by Type
- 7.2.2 Analysis by Therapy
- 7.2.3 Analysis by Route of Administration
- 8 Osteoporosis Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Osteoporosis Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Osteoporosis Market Segmentation- Seven Major Markets
- 11.1 Osteoporosis Market by Type
- 11.1.1 Market Overview
- 11.1.2 Primary Osteoporosis
- 11.1.3 Secondary Osteoporosis
- 11.2 Osteoporosis Market by Therapy
- 11.2.1 Market Overview
- 11.2.2 Bisphosphonates
- 11.2.3 Selective Estrogen Receptor Modulators
- 11.2.4 Parathyroid Hormone Therapy
- 11.2.5 RANK Ligand Inhibitors
- 11.3 Osteoporosis Market by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Injectable
- 11.3.4 Others
- 11.4 Osteoporosis Market by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals
- 11.4.3 Specialty Clinics
- 11.4.4 Home Healthcare
- 11.4.5 Others
- 11.5 Osteoporosis Market by Distribution Channel
- 11.5.1 Market Overview
- 11.5.2 Hospitals
- 11.5.3 Retail Pharmacies
- 11.5.4 Online Pharmacies
- 11.5.5 Others
- 11.6 Osteoporosis Market by Region
- 11.6.1 Market Overview
- 11.6.2 United States
- 11.6.3 EU-4 and the United Kingdom
- 11.6.3.1 Germany
- 11.6.3.2 France
- 11.6.3.3 Italy
- 11.6.3.4 Spain
- 11.6.3.5 United Kingdom
- 11.6.4 Japan
- 12 United States Cervical Dystonia Market
- 12.1 Cervical Dystonia Market Historical Value (2018-2024)
- 12.2 Cervical Dystonia Market Forecast Value (2025-2034)
- 12.3 Cervical Dystonia Market by Type
- 12.4 Cervical Dystonia Market by Therapy
- 13 EU-4 and United Kingdom Cervical Dystonia Market
- 13.1 Cervical Dystonia Market Historical Value (2018-2024)
- 13.2 Cervical Dystonia Market Forecast Value (2025-2034)
- 13.3 Germany Cervical Dystonia Market Overview
- 13.3.1 Cervical Dystonia Market by Type
- 13.3.2 Cervical Dystonia Market by Therapy
- 13.4 France Cervical Dystonia Market Overview
- 13.4.1 Cervical Dystonia Market by Type
- 13.4.2 Cervical Dystonia Market by Therapy
- 13.5 Italy Cervical Dystonia Market Overview
- 13.5.1 Cervical Dystonia Market by Type
- 13.5.2 Cervical Dystonia Market by Therapy
- 13.6 Spain Cervical Dystonia Market Overview
- 13.6.1 Cervical Dystonia Market by Type
- 13.6.2 Cervical Dystonia Market by Therapy
- 13.7 United Kingdom Cervical Dystonia Market Overview
- 13.7.1 Cervical Dystonia Market by Type
- 13.7.2 Cervical Dystonia Market by Therapy
- 14 Japan Cervical Dystonia Market
- 14.1 Cervical Dystonia Market Historical Value (2018-2024)
- 14.2 Cervical Dystonia Market Forecast Value (2025-2034)
- 14.3 Cervical Dystonia Market by Type
- 14.4 Cervical Dystonia Market by Therapy
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnership and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 DAIICHI SANKYO COMPANY
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisition
- 21.1.5 Certifications
- 21.2 Amgen Inc.
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisition
- 21.2.5 Certifications
- 21.3 Merck & Co., Inc
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisition
- 21.3.5 Certifications
- 21.4 AbbVie Inc
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisition
- 21.4.5 Certifications
- 21.5 Bayer AG
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisition
- 21.5.5 Certifications
- 21.6 Johnson & Johnson Services, Inc.
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisition
- 21.6.5 Certifications
- 21.7 Sanofi.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisition
- 21.7.5 Certifications
- 21.8 Bristol-Myers Squibb Company
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisition
- 21.8.5 Certifications
- 21.9 Takeda Pharmaceutical Company Limited
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisition
- 21.9.5 Certifications
- 21.10 Pfizer Inc.
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisition
- 21.10.5 Certifications
- 21.11 Astrazeneca
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisition
- 21.11.5 Certifications
- 21.12 Eli Lilly And Company
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisition
- 21.12.5 Certifications
- 21.13 Novartis AG
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisition
- 21.13.5 Certifications
- 21.14 F. Hoffmann-La Roche Ltd
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisition
- 21.14.5 Certifications
- 21.15 GlaxoSmithKline plc.
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisition
- 21.15.5 Certifications
- 22 Osteoporosis Market - Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
